Data Article

Data on arsenic trioxide modulates Treg/Th17/Th1/Th2 cells in treatment-naïve rheumatoid arthritis patients and collagen-induced arthritis model mice

Chunling Li, Juan Zhang, Weiyan Wang, Hui Wang, Yue Zhang, Zhiyi Zhang

Department of Rheumatology, The First Affiliated Hospital, Harbin Medical University, Harbin, China
Shenzhen Futian Hospital for Rheumatic Diseases, Shenzhen, China

A R T I C L E   I N F O

Article history:
Received 3 May 2019
Received in revised form 25 September 2019
Accepted 26 September 2019
Available online 15 October 2019

Keywords:
Arsenic trioxide
Rheumatoid arthritis
Collagen induced arthritis
Regulatory T cell
T helper 17 cell
T helper 1 cell
T helper 2 cell

A B S T R A C T

In this article, we share the raw protein and mRNA data obtained from basal and stimulated human peripheral blood mononuclear cells (PBMCs) derived from 15 individual treatment-naïve rheumatoid arthritis (RA) patients and synovial fluid mononuclear cells (SFMCs). In treatment-naïve RA patients, PBMCs were treated with a gradient of concentrations of As2O3 (0, 0.1, 0.5, 1.0, 2.0, 4.0 μM) for 48 hours. We found that 2.0 μM As2O3 promoted the apoptosis of PBMCs significantly, and 0.5 μM As2O3 was the lowest and effective concentration that contributed to Treg cell generation but prevented Th17 cell differentiation, as assessed by flow cytometry. Furthermore, As2O3 decreased the transcription factor STAT3 mRNA expression of Th17 cells but increased the transcription factor Foxp3 of Treg cells. In synovial fluid from RA patients, consistent with PBMCs, As2O3 inhibited Th17 cell differentiation but promoted Treg cell generation. In an animal experiment, we analyzed the body-weight of mice as the indicator of As2O3 toxicity and calculated the spleen index. As2O3 significantly decreased the hematoxylin and eosin score in Type II collagen-induced arthritis in mice. Furthermore, As2O3 downregulated the frequency of Th1 but upregulated Th2 cells. For more insight please see Arsenic

DOI of original article: https://doi.org/10.1016/j.intimp.2019.05.001.

* Corresponding author. Department of Rheumatology, The First Affiliated Hospital, Harbin Medical University, Harbin, China.
** Corresponding author.
1 Currently, Department of Rheumatology, Henan Provincial People’s Hospital; People’s Hospital of Zhengzhou University, Zhengzhou, Henan, 450003, China.

https://doi.org/10.1016/dib.2019.104615
2352-3409/© 2019 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Arsenic trioxide improves Treg and Th17 balance by modulating STAT3 in treatment-naive rheumatoid arthritis patients [1].

© 2019 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Data

All treatment naïve-RA patients related clinical indicators were provided in Table 1 and flow cytometry panels can be referred in Table 2. $\text{As}_2\text{O}_3$ significantly promotes the apoptosis of CD4$^+$ T cells at a concentration of 2.0 $\mu$M in a dose-dependent manner (Fig. 1A, B, Table 3). We also detected the effect of $\text{As}_2\text{O}_3$ on rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) viability. The data
showed that there is no significant change in cell viability (Fig. 1C) [2]. As$_2$O$_3$ at the lowest effective concentration of 0.5 μM selectively inhibited the differentiation of CD4$^+$T cells into IL-17$^+$CD4$^+$T cells (Fig. 2A, Table 4) but contributed to Foxp3$^+$CD4$^+$T cell generation (Fig. 2B, Table 4) in the presence of special polarizing cytokines. Furthermore, in parallel with the previous results, As$_2$O$_3$ downregulated the STAT3 mRNA expression of Th17 cells (Fig. 2C, Table 4) but upregulated the Foxp3 mRNA expression of Treg cells (Fig. 2D, Table 4). Additionally, we also detected Treg and Th17 cells in synovial fluid from RA patients. The percentage of Treg (11.6%) and Th17 cells (55.1%) was higher in synovial fluid (SF) than that in peripheral blood (PB). We found that As$_2$O$_3$ at the concentration of 0.5 μM increased the frequency of Treg cells (Fig. 3A) but decreased Th17 cells (Fig. 3B, Table 5).

To further study the effects of As$_2$O$_3$ on CD4$^+$T cell proliferation and differentiation, a Type II collagen-induced arthritis (CIA) mouse model was constructed and the groups were divided as described previously [3]. First, we assessed the severity of arthritis from Day 19 after primary immunization according to a standard score system [1]. Second, we used body-weight as the indicator of As$_2$O$_3$ toxicity. As$_2$O$_3$ (1.0, 2.0 or 5.0 mg/kg/day) did not markedly affect the body-weight of CIA mice.

Table 1
Clinical characteristics of treatment-naïve RA patients who provided synovial fluid. PB, peripheral blood; SF, synovial fluid; RF, rheumatoid factor; CCP, citrullinated peptide; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; DAS28, disease activity score 28; TJc, tender joint count; SJC, swollen joint count; VAS, visual analog score.

| Patient identifier | Sample | Diagnosis | Gender | Age (yrs) | Age at onset of RA (yrs) | Dis. RF | CCP | ESR | CRP | DAS28 | TJc | SJC | VAS | Figures |
|--------------------|--------|-----------|--------|-----------|-------------------------|---------|-----|-----|-----|-------|-----|-----|-----|---------|
| 1 PB RA F 57 27 30 | pos | neg | pos | pos | 6.67 | 11 | 11 | 7 | 1A,B |
| 2 PB RA M 48 41 7 | pos | pos | pos | pos | 6.68 | 22 | 0 | 5 | 1A,B, 2A–D |
| 3 PB RA F 55 54 1 | pos | pos | pos | pos | 8.19 | 24 | 24 | 7 | 1A,B |
| 4 PB RA F 69 66 3 | pos | pos | pos | pos | 4.42 | 0 | 2 | 5 | 2A–D |
| 5 PB RA M 41 41 0.5 | pos | pos | neg | pos | 3.91 | 2 | 2 | 5 | 2A–D |
| 6 PB RA F 55 41 14 | neg | pos | pos | pos | 7.48 | 21 | 21 | 6 | 2A–D |
| 7 PB RA F 46 39 7 | neg | neg | pos | neg | 2.16 | 0 | 0 | 5 | 1A,B |
| 8 PB RA F 38 38 0.33 | pos | pos | pos | pos | 8.21 | 26 | 26 | 7 | 2A–D |
| 9 PB RA M 63 47 16 | pos | pos | pos | pos | 5.87 | 10 | 1 | 6 | 2A–D |
| 10 SF RA F 67 66 1 | pos | pos | pos | pos | 5.87 | 4 | 4 | 6 | 3A,B |
| 11 SF RA M 52 51 1 | pos | pos | pos | pos | 6.66 | 11 | 10 | 7 | 3A,B |
| 12 SF RA F 41 32 9 | pos | pos | neg | pos | 5.4 | 6 | 6 | 8 | 3A,B |
| 13 SF RA F 48 48 0.58 | pos | pos | neg | pos | 4.97 | 2 | 2 | 6 | 3A,B |
| 14 SF RA F 61 31 30 | pos | neg | pos | pos | 5.19 | 8 | 2 | 6 | 3A,B |
| 15 SF RA F 48 48 0.58 | neg | pos | pos | pos | 5.78 | 8 | 8 | 6 | 3A,B |

Table 2
Antibodies and immunostaining panels used for flow cytometry. Detailed description of the fluorochrome-conjugated antibodies and immunostaining panels used to immunophenotype and flow sort the assessed CD4$^+$T cell populations.

| Immunostaining Panel | Antibody | Fluorochrome | Clone | Manufacture |
|----------------------|-----------|--------------|-------|-------------|
| Human Treg Immunophenotyping (Freshly isolated PBMCs) | CD4 | FITC | 13B8.2 | Beckman Coulter |
| CD25 | PE | BL49.9 | Beckman Coulter |
| CD127 | PE-Cy5 | R34.34 | Beckman Coulter |
| Foxp3 | BV421 | 206D | Biolegend |
| Human Th17 Immunophenotyping (Freshly isolated PBMCs) | CD4 | FITC | 13B8.2 | Beckman Coulter |
| IL-17 | PE | SCPL1362 | 3-ekcmn Coulter |
| CCR3 | PE | G02S1H7 | 3iolegend |
| CCR6 | APC | G034E3 | 3iolegend |
| Mouse Th1 Immunophenotyping (Freshly isolated PBMCs) | CD4 | FITC | RM4-5 | Biolegend |
| IFN-γ | PE | XMG1.2 | Biolegend |
| IC | PE | RTK2071 | Biolegend |
| Mouse Th2 Immunophenotyping (Freshly isolated PBMCs) | CD4 | FITC | RM4-5 | Biolegend |
| IL-4 | PE-Cy7 | 11B11 | 3iolegend |
| IC | PE-Cy7 | RTK2071 | 3iolegend |

IC: Isotype control
As$_2$O$_3$ shows an apoptotic effect on CD4$^+$ T cells from 2.0 µM. (A). Apoptosis of CD4$^+$ T cells from treatment-naïve RA patients was detected by flow cytometry. (B). Quantification of the apoptosis percentage. (C). The effect of As$_2$O$_3$ and vitamin D on RA FLS viability, as evaluated by cell count kit 8 (CCK8) assay. **p<0.05 vs non-treatment group, ***p<0.001 vs non-treatment group by unpaired Student t-test. Additionally, mean values, S.E.M and Tukey’s multiple comparisons statistics (post hoc) are shown in tabular form below their respective graphs.
compared with CIA control mice (Table 6). Interestingly, As2O3 reduced the size of spleen tissues and also decreased the spleen index (spleen weight/mice weight) (Fig. 4A, Table 7). Hematoxylin and eosin (H&E) staining revealed that As2O3 (2.0 or 5.0 mg/kg/day) significantly decreased splenic corpuscle proliferation and inflammatory infiltration (Fig. 4B, Table 7). We also found that As2O3 upregulated the percentage of Th2 cells but downregulated Th1 cells in the spleen (Fig. 5A, B, Table 7).

2. Experimental design, materials and methods

2.1. Treatment-naive RA patients

Treatment-naive RA patients who fulfilled the American College of Rheumatology 1987 revised criteria [4] were enrolled in the study. Treatment-naive RA patients were recruited from the
Department of Rheumatology of the First Affiliated Hospital of Harbin Medical University. Some patients were taking nonsteroidal anti-inflammatory drugs; none of the patients had been receiving disease-modifying antirheumatic drugs or corticosteroids. The study was conducted with formal approval from the Ethical Committee of Harbin Medical University.

Table 4
The effects of As$_2$O$_3$ on the differentiation of CD$^+$ T cells under special polarizing cytokines. Th17 cells: Anti-CD3 (2 μg/mL), Anti-CD28 (4 μg/mL), IL-1β (10 ng/mL), IL-6 (20 ng/mL), IL-23 (100 ng/mL), TGF-β (1 ng/mL). iTreg cells: Anti-CD3 (2 μg/mL), Anti-CD28 (4 μg/mL), IL-2 (20 U/mL), TGF-β (2 ng/mL).

| As$_2$O$_3$ (μM) | Th17 cells (%) | STAT3 gene expression | Treg cells (%) | Foxp3 gene expression |
|------------------|----------------|-----------------------|----------------|----------------------|
| veh              | 0.2            | 0.9                   | 4.2            | 1.2                  |
| 0.5              | 1.5            | 2.5                   | 5.0            | 2.0                  |
| 0.8              | 1.0            | 3.5                   | 3.0            | 1.2                  |
| 1.2              | 0.6            | 5.0                   | 4.0            | 0.5                  |
| 0.1              | 0.8            | 3.0                   | 1.5            | 1.5                  |
| 0.3              | 1.8            | 4.0                   | 2.0            | 2.0                  |
| 0                | 4.5            | 2.2                   | 7.5            | 1.5                  |
| 4.3              | 2.5            | 6.4                   | 2.0            | 2.0                  |
| 3.5              | 2.1            | 8.5                   | 2.4            | 2.4                  |
| 5.8              | 2.5            | 6.5                   | 2.5            | 2.5                  |
| 13               | 2.0            | 7.5                   | 1.5            | 1.5                  |
| 5.0              | 1.8            | 8.0                   | 1.4            | 1.4                  |
| 0.5              | 2.0            | 9.0                   | 1.8            | 1.8                  |
| 4.0              | 2.4            | 9.8                   | 2.3            | 2.3                  |
| 2.8              | 1.5            | 7.0                   | 2.5            | 2.5                  |
| 3.0              | 1.0            | 8.0                   | 3.5            | 3.5                  |
| 1.5              | 12             | 8.5                   | 3.0            | 3.0                  |
| 2.0              | 0.8            | 9.5                   | 2.5            | 2.5                  |

Fig. 3. As$_2$O$_3$ increased the frequency of Treg cells (A) but decreased Th17 cells (B) in synovial fluid from RA patients, as assessed by flow cytometry. The results shown are representative of six independent experiments (n = 6).
2.2. Peripheral blood and synovial fluid mononuclear cell isolation of naïve CD4+ T cells

PBMCs were isolated from treatment-naïve RA patients and healthy volunteers. Synovial fluid mononuclear cells were isolated from synovial fluid from RA patients, then separated by density

**Table 5**
The effects of As$_2$O$_3$ on the Treg and Th17 cells from synovial fluid.

| As2O3 (μM) | Percentage (%) (n = 6) |
|------------|------------------------|
|            | Treg       | Th17       |
| 0          | 11.6       | 55.1       |
| 12.5       | 58.2       |
| 13.4       | 52.8       |
| 10.5       | 56.5       |
| 9.5        | 50.3       |
| 9.4        | 54.6       |
| 0.5        | 16.3       | 40.8       |
| 18.5       | 35.3       |
| 15.4       | 37.5       |
| 13.3       | 34.8       |
| 17.5       | 42.7       |
| 18.4       | 32.9       |

**Table 6**
The effects of As$_2$O$_3$ on body-weight. The body-weight was detected from Day 34 to Day 40. MTX: methotrexate.

| Body weight (g) | Days from first immunization |
|-----------------|-------------------------------|
|                 | 34   | 35   | 36   | 37   | 38   | 39   | 40   |
| NC              | 20.5 | 20.6 | 20.7 | 21.0 | 21.3 | 21.7 | 21.7 |
| NC              | 19.6 | 19.7 | 19.8 | 19.9 | 20.1 | 20.3 | 20.6 |
| NC              | 20.3 | 20.3 | 21.3 | 21.3 | 21.3 | 21.7 | 21.7 |
| NC              | 16.4 | 16.7 | 16.9 | 17.2 | 17.8 | 17.9 | 17.9 |
| NC              | 17.9 | 18.0 | 18.2 | 18.4 | 18.5 | 18.7 | 18.8 |
| CIA             | 15.3 | 15.9 | 15.7 | 15.7 | 16.1 | 17.0 | 16.9 |
| CIA             | 16.3 | 16.3 | 15.4 | 15.5 | 15.6 | 16.0 | 16.4 |
| CIA             | 16.0 | 15.9 | 15.7 | 15.5 | 15.6 | 15.8 | 16.8 |
| CIA             | 19.0 | 18.8 | 18.2 | 18.0 | 18.2 | 18.1 | 18.0 |
| CIA             | 16.8 | 16.5 | 16.3 | 16.3 | 16.3 | 16.9 | 17.3 |
| 1.0             | 20.0 | 20.1 | 19.5 | 19.9 | 20.2 | 20.6 | 21.2 |
| 1.0             | 20.9 | 20.6 | 20.4 | 20.5 | 21.1 | 21.4 | 21.7 |
| 1.0             | 20.8 | 21.2 | 20.7 | 21.2 | 21.4 | 21.7 | 21.8 |
| 1.0             | 17.8 | 17.7 | 17.3 | 18.0 | 18.5 | 19.2 | 19.2 |
| 1.0             | 19.5 | 19.4 | 19.4 | 19.2 | 19.2 | 19.0 | 19.1 |
| 2.0             | 16.6 | 16.1 | 16.4 | 16.2 | 17.4 | 17.4 | 18.1 |
| 2.0             | 20.6 | 20.7 | 19.9 | 20.1 | 20.3 | 20.7 | 20.5 |
| 2.0             | 19.0 | 18.7 | 19.3 | 18.5 | 18.7 | 19.1 | 19.2 |
| 2.0             | 18.8 | 18.2 | 18.0 | 18.3 | 18.8 | 19.5 | 19.2 |
| 2.0             | 19.5 | 19.2 | 18.9 | 19.0 | 20.2 | 20.0 | 20.1 |
| 5.0             | 16.9 | 17.3 | 16.7 | 17.6 | 17.4 | 18.0 | 18.5 |
| 5.0             | 20.6 | 17.7 | 17.6 | 16.9 | 17.6 | 17.7 | 17.5 |
| 5.0             | 18.7 | 20.8 | 20.8 | 21.2 | 20.8 | 21.2 | 21.5 |
| 5.0             | 16.8 | 17.3 | 17.2 | 17.8 | 18.0 | 18.2 | 19.3 |
| 5.0             | 19.2 | 20.7 | 20.7 | 21.5 | 21.4 | 22.0 | 21.9 |
| MTX             | 16.9 | 17.1 | 17.4 | 18.1 | 18.5 | 19.4 | 19.6 |
| MTX             | 17.9 | 20.5 | 21.4 | 21.9 | 22.0 | 22.0 | 21.7 |
| MTX             | 21.0 | 18.8 | 19.1 | 19.0 | 19.6 | 20.1 | 20.2 |
| MTX             | 17.6 | 16.8 | 16.6 | 17.1 | 17.2 | 17.9 | 17.9 |
| MTX             | 20.5 | 19.1 | 19.3 | 19.5 | 19.4 | 19.2 | 19.3 |
gradient on a Ficoll-Hypaque apparatus (MD Pacific Biotechnology, Tianjin, China). Naïve CD4⁺ T lymphocytes were purified on a high-speed cell sorter system (MoFlo XDP, Beckman Coulter, Indianapolis, IN, USA). The naïve CD4⁺ T cells had a purity of >95%, which was confirmed by flow cytometry (FC500, Beckman Coulter, Indianapolis, IN, USA).

**Fig. 4.** The effects of As₂O₃ on spleen tissues. (A). As₂O₃ decreased the volume of the spleen. (B). The spleen index in the CIA control group increased significantly compared with the normal control group. However, the spleen index of groups under As₂O₃ (2.0 or 5.0 mg/kg/day) and MTX treatment decreased significantly compared with the CIA control group. Splenic corpuscle proliferation and splenic sinus congestion in the CIA group increased significantly compared with the normal control group. However, splenic corpuscle proliferation and splenic sinus congestion in the As₂O₃ and MTX treatment groups decreased significantly compared with the CIA control group.

**Table 7**

The effects of As₂O₃ on spleen tissues. Percentage of Th1 and Th2 cells in spleen lymphocytes. Were detected by flow cytometry.

| Group (n = 5) | As₂O₃ (mg kg day) | Index of spleen | Spleen Histological score | Th1 (%) | Th2 (%) |
|--------------|-------------------|----------------|---------------------------|---------|---------|
| NC           | 2.1               | 0.8            | 1.9                       | 5.2     |
| NC           | 2.2               | 1.1            | 1.5                       | 6.0     |
| NC           | 1.9               | 1.2            | 2.0                       | 5.5     |
| NC           | 1.8               | 1.0            | 1.8                       | 4.5     |
| NC           | 2.0               | 1.3            | 1.3                       | 5.0     |
| CIA          | 4.8               | 2.7            | 4.5                       | 2.2     |
| CIA          | 4.6               | 2.6            | 5.0                       | 2.0     |
| CIA          | 5.1               | 2.5            | 4.0                       | 1.5     |
| CIA          | 5.2               | 3.2            | 5.5                       | 2.5     |
| CIA          | 4.5               | 3.5            | 3.5                       | 1.8     |
| 1.0          | 4.0               | 2.3            | 4.3                       | 2.8     |
| 1.0          | 4.3               | 2.4            | 5.0                       | 2.3     |
| 1.0          | 4.5               | 2.1            | 3.5                       | 2.0     |
| 1.0          | 4.2               | 2.8            | 4.8                       | 3.5     |
| 1.0          | 3.9               | 3.0            | 3.0                       | 3.2     |
| 2.0          | 3.6               | 1.8            | 3.5                       | 3.8     |
| 2.0          | 3.9               | 2.0            | 4.0                       | 2.9     |
| 2.0          | 4.0               | 1.7            | 3.0                       | 3.0     |
| 2.0          | 4.2               | 2.0            | 4.2                       | 3.5     |
| 2.0          | 3.2               | 2.8            | 3.0                       | 4.0     |
| 5.0          | 3.4               | 1.4            | 2.7                       | 4.2     |
| 5.0          | 3.2               | 1.1            | 2.5                       | 4.5     |
| 5.0          | 3.0               | 1.7            | 3.0                       | 4.0     |
| 5.0          | 3.5               | 1.2            | 1.5                       | 3.5     |
| 5.0          | 2.9               | 2.0            | 2.2                       | 4.8     |
| MTX          | 2.6               | 1.2            | 2.5                       | 4.8     |
| MTX          | 3.0               | 1.3            | 2.2                       | 4.3     |
| MTX          | 2.8               | 1.5            | 3.0                       | 3.9     |
| MTX          | 3.2               | 1.8            | 1.4                       | 5.2     |
| MTX          | 2.7               | 1.0            | 2.1                       | 5.0     |
2.3. Apoptosis assay

Sorted live CD4\(^+\) T cells from treatment-naive RA patients were cultured in the presence of different concentrations of As\(_2\)O\(_3\) for 48 hours. Apoptosis was determined by Annexin V and propidium iodide staining according to the manufacturer’s protocol (BD Biosciences, San Diego, CA, USA). When gated on total cells, Annexin V- and propidium iodide-negative cells were considered as living. No significant changes in total cell numbers were observed. Samples were analyzed by flow cytometry (FC 500, Beckman Coulter, Indianapolis, IN, USA).

2.4. In vitro stimulation polarization of CD4\(^+\) T cells

CD4\(^+\) T cells were cultured with anti-CD3 (2 \(\mu\)g/mL)/anti-CD28 (4 \(\mu\)g/mL) (Biolegend, San Diego, CA). IL-1 \(\beta\) (10 ng/mL), IL-6 (20 ng/mL), TGF-\(\beta\) (1 ng/mL) (Biolegend, San Diego, CA), IL-23 (100 ng/mL) (R&D Systems, Minneapolis, USA) were added for Th17 cell polarization; TGF-\(\beta\) (2 ng/mL) and IL-2 (20 U/mL) (Biolegend, San Diego, CA) were added for Treg cell polarization. At the same time, As\(_2\)O\(_3\) (0.5 \(\mu\)M) (Yitaida Pharmaceutical Factory, Harbin, Heilongjiang, China) was added once a day for 3 days.

2.5. In vitro proliferation assay

The cell proliferation assay was evaluated with a Cell Counting Kit-8 (Sigma, St Louis, MO, USA) following the procedures described earlier with minor modifications [5]. Briefly, \(10^4\) cells were seeded in a 96-well plate. After 24 h, different concentrations of drugs or vehicles were added with fresh medium. Cells were incubated at 37 \(^\circ\)C for 48 h before detected at 450 nm immediately. The experiments were repeated three times.

2.6. Flow cytometry analysis

For intracellular cytokines detection, cells were stimulated with the corresponding cell activation cocktail (with Brefeldin A) (Biolegend, San Diego, CA) for 6 h. After surface staining for 15 min, the cells
were resuspended in a fixation buffer, and washed three times with a permeabilization solution (Biolegend, San Diego, CA) for 5 mins each at 1500 rpm. Intracellular cytokine staining was performed according to the manufacturer’s protocol. Isotype control staining consistently resulted in 0.1% positive cells throughout the experiments. The following reagents were used for human experiments: fluorescein isothiocyanate-conjugated CD4 (clone: 13B8.2), biotinylated and phycoerythrin-conjugated CD25 (clone: B1.49.9), peridinin chlorophyll A protein-Cy5-conjugated CD127 (clone: R34.34), allophycocyanin-conjugated CCR6 (clone: G034E3) and phycoerythrin-conjugated CXCR3 (clone: G025H7). All these antibodies were purchased from Beckman Coulter (San Diego, CA, USA). The following reagents were used for mouse assays: anti-CD4-FITC (clone: RM4-5), anti-IFN-γ phycoerythrin (clone: XMG1.2) and anti-IL-4-PC7 (clone: 11B11). All these antibodies were purchased from Biolegend (San Diego, CA, USA).

2.7. Real-time quantitative polymerase chain reaction analysis

The methods used for RNA extraction and cDNA synthesis have been described previously [3]. Data were normalized to glyceraldehyde-3-phosphate dehydrogenase and β-actin, and were calculated via the 2^ΔΔCt method.

2.8. Animal model and experimental protocol

Male DBA/1 J mice (5–8 weeks old, 20 g ± 2 g in weight; Charles River, Beijing, China) were housed under specific pathogen-free conditions at the veterinary institute of Harbin Medical University and were fed with standard mouse chow and water. All experimental procedures were examined and approved by the Institutional Animal Care and Use Committee of Harbin Medical University. The method for the CIA mouse model was performed in our laboratory as described previously [3]. The scoring system was used according to a protocol described previously [6]. The mice were carefully monitored for toxicity symptoms and weighed every 3 days. The mean body-weight and spleen index of each group were calculated and used as a parameter of toxicity.

2.9. Histology analysis

Mice spleens were collected after sacrifice. The procedures of fixation and embedding have been described previously [3]. In brief, the spleens were embedded in paraffin, cut into 5-μm sections and stained with H&E. Histology scores were assessed as previously described [3].

2.10. Spleen lymphocyte preparation

Mice were sacrificed, then spleens were drained and by passing through a 200 μm wire mesh to obtain single-cell suspensions. PBMCs were isolated by Ficoll density gradient isolation (Haoyang, Tianjin, China) according to the manufacturer’s instructions. Mononuclear cells were obtained and resuspended in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 100 IU/mL of penicillin, 100 μg/ml of streptomycin, nonessential amino acids, 1 μM sodium pyruvate and 2 mM L-glutamine. Subsequently, flow cytometry detected the percentage of Th1 and Th2 cells.

2.11. Statistical analysis

The data were analyzed by using GraphPad Prism Software (Version 6 for Windows; Graphpad Prism, San Diego, CA, USA). Simple comparisons were conducted with unpaired, two-tailed Students’s t-test for parametric data. Values of P < 0.05 were considered statistically significant. All data were expressed as mean ± S.E.M.
**Acknowledgments**

We are grateful to Ms. Yanli Wang for technical assistance with flow cytometry and Yu Wang for providing synovial fluid. This work is supported by National Science Foundation of China, Grant No. 81273291, No. 81771749 and No. 81771748.

**Conflict of Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**References**

[1] C. Li, J. Zhang, W. Wang, H. Wang, Y. Zhang, Z. Zhang, Arsenic trioxide improves Treg and Th17 balance by modulating STAT3 in treatment-naive rheumatoid arthritis patients, Int. Immunopharmacol. 73 (2019) 539–551, https://doi.org/10.1016/j.intimp.2019.05.001.

[2] W. Wang, C. Li, Y. Zhang, Z. Zhang, Arsenic trioxide synergistic with vitamin D rescues the defective VDR-PPARγ autophagy functional module in rheumatoid arthritis, PPAR Res. 2019 (2019), 6403504, https://doi.org/10.1155/2019/6403504.

[3] J. Zhang, C. Li, Y. Zhang, Z. Lin, Y. Zhang, Z. Zhang, Inhibition of angiogenesis by arsenic trioxide via TSP-1-TGF-β1-CTGF-VEGF functional module in rheumatoid arthritis, OncoTargets 8 (43) (2017) 73529–73546, https://doi.org/10.18632/oncotarget.19867.

[4] F. Arnett, S. Edworthy, D. Bloch, D. McShane, J. Fries, N. Cooper, et al., The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis Rheum. 31 (3) (1988) 315–324, https://doi.org/10.1002/art.1780310302.

[5] X. Wang, Y. Zhang, Z. Han, K. He, Malignancy of cancers and synthetic lethal interactions associated with mutations of cancer driver genes, Medicine (Baltim.) 95 (8) (2016) e2697, https://doi.org/10.1097/MD.0000000000002697.

[6] D. Brand, K. Latham, E. Rosloniec, Collagen-induced arthritis, Nat. Protoc. 2 (5) (2007) 1269–1275, https://doi.org/10.1038/nprot.2007.173.